- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Castellani: Health Law's Cost-Sharing Could Limit Patient Access To Prescription Drugs
Enrollees in some of the health law's most popular plans will face high cost-sharing requirements that the pharmaceutical industry says could keep patients from getting the drugs they need.
Enrollees in some of the health law’s most popular plans will face high cost-sharing requirements that the pharmaceutical industry says could keep patients from getting the drugs they need.
Most silver plans in the online marketplaces, or exchanges, require patients to pay for prescription drugs as part of the plan’s deductible, while nearly all bronze plans do, according to a report from Breakaway Health prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA), the drug industry’s trade group.
Silver plans that combine prescription and medical costs into one deductible — the out-of-pocket costs patients pay before coverage begins — have average deductibles of $2,275, and similar bronze plans have an average of $4,986, according to the report. The average amount for plans that have separate prescription drug deductibles is $470 for a silver plan and $956 for a bronze one.
Read the full story here: http://bit.ly/1jjNSEP
Source: Kaiser Health News
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
